$TEVA

2023 Q3 Form 10-Q Financial Statement

#000119312523274495 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2022 Q3
Revenue $3.850B $3.595B
YoY Change 7.09% -7.51%
Cost Of Revenue $1.999B $1.926B
YoY Change 3.79% -3.17%
Gross Profit $1.851B $1.669B
YoY Change 10.9% -12.07%
Gross Profit Margin 48.08% 46.43%
Selling, General & Admin $844.0M $822.0M
YoY Change 2.68% -4.86%
% of Gross Profit 45.6% 49.25%
Research & Development $253.0M $175.0M
YoY Change 44.57% -21.17%
% of Gross Profit 13.67% 10.49%
Depreciation & Amortization $283.0M $321.0M
YoY Change -11.84% -2.43%
% of Gross Profit 15.29% 19.23%
Operating Expenses $1.097B $997.0M
YoY Change 10.03% -8.7%
Operating Profit $355.0M $419.0M
YoY Change -15.27% -48.01%
Interest Expense -$247.0M -$230.0M
YoY Change 7.39% -9.45%
% of Operating Profit -69.58% -54.89%
Other Income/Expense, Net -$280.0M -$252.0M
YoY Change 11.11% -2038.46%
Pretax Income $75.00M $166.0M
YoY Change -54.82% -56.54%
Income Tax -$12.00M $107.0M
% Of Pretax Income -16.0% 64.46%
Net Earnings $80.00M $56.00M
YoY Change 42.86% -80.69%
Net Earnings / Revenue 2.08% 1.56%
Basic Earnings Per Share $0.07 $0.05
Diluted Earnings Per Share $0.07 $0.05
COMMON SHARES
Basic Shares Outstanding 1.121B 1.111B
Diluted Shares Outstanding 1.135B 1.119B

Balance Sheet

Concept 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.249B $2.225B
YoY Change 1.08% 8.8%
Cash & Equivalents $2.249B $2.225B
Short-Term Investments
Other Short-Term Assets $520.0M $579.0M
YoY Change -10.19% -69.46%
Inventory $4.051B $3.859B
Prepaid Expenses $1.168B $1.045B
Receivables $3.385B $3.730B
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.43B $11.45B
YoY Change -0.24% -5.77%
LONG-TERM ASSETS
Property, Plant & Equipment $5.622B $5.568B
YoY Change 0.97% -14.95%
Goodwill $16.89B $18.43B
YoY Change -8.4% -8.65%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $477.0M $438.0M
YoY Change 8.9% -61.55%
Total Long-Term Assets $30.66B $32.80B
YoY Change -6.51% -8.12%
TOTAL ASSETS
Total Short-Term Assets $11.43B $11.45B
Total Long-Term Assets $30.66B $32.80B
Total Assets $42.09B $44.25B
YoY Change -4.89% -7.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.280B $1.635B
YoY Change 39.45% 7.99%
Accrued Expenses $3.271B $2.537B
YoY Change 28.93% -2.05%
Deferred Revenue
YoY Change
Short-Term Debt $523.0M $23.00M
YoY Change 2173.91% -92.88%
Long-Term Debt Due $956.0M $2.746B
YoY Change -65.19% 15.09%
Total Short-Term Liabilities $11.39B $11.53B
YoY Change -1.21% -2.46%
LONG-TERM LIABILITIES
Long-Term Debt $18.50B $18.50B
YoY Change -0.01% -12.07%
Other Long-Term Liabilities $3.818B $3.846B
YoY Change -0.73% 46.35%
Total Long-Term Liabilities $23.18B $23.20B
YoY Change -0.08% -1.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.39B $11.53B
Total Long-Term Liabilities $23.18B $23.20B
Total Liabilities $34.58B $34.73B
YoY Change -0.45% -7.09%
SHAREHOLDERS EQUITY
Retained Earnings -$13.87B -$11.66B
YoY Change 18.95%
Common Stock $57.00M $57.00M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.128B $4.128B
YoY Change 0.0%
Treasury Stock Shares $106.0M
Shareholders Equity $6.929B $8.767B
YoY Change
Total Liabilities & Shareholders Equity $42.09B $44.25B
YoY Change -4.89% -7.52%

Cashflow Statement

Concept 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income $80.00M $56.00M
YoY Change 42.86% -80.69%
Depreciation, Depletion And Amortization $283.0M $321.0M
YoY Change -11.84% -2.43%
Cash From Operating Activities $5.000M $544.0M
YoY Change -99.08% 2.84%
INVESTING ACTIVITIES
Capital Expenditures $149.0M -$122.0M
YoY Change -222.13% -16.44%
Acquisitions $0.00 $0.00
YoY Change
Other Investing Activities $1.000M $269.0M
YoY Change -99.63% -38.02%
Cash From Investing Activities $184.0M $147.0M
YoY Change 25.17% -48.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $1.000B $365.0M
YoY Change 173.97%
Cash From Financing Activities -576.0M -440.0M
YoY Change 30.91% -62.62%
NET CHANGE
Cash From Operating Activities 5.000M 544.0M
Cash From Investing Activities 184.0M 147.0M
Cash From Financing Activities -576.0M -440.0M
Net Change In Cash -420.0M 251.0M
YoY Change -267.33% -169.72%
FREE CASH FLOW
Cash From Operating Activities $5.000M $544.0M
Capital Expenditures $149.0M -$122.0M
Free Cash Flow -$144.0M $666.0M
YoY Change -121.62% -1.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000818686
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Address Country
EntityAddressCountry
IL
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-16174
dei Entity Registrant Name
EntityRegistrantName
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
dei Entity Address Address Line1
EntityAddressAddressLine1
124 Dvora HaNevi’a St.
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6944020
dei City Area Code
CityAreaCode
+972 (3)
dei Local Phone Number
LocalPhoneNumber
914-8213
dei Security12b Title
Security12bTitle
American Depositary Shares, each representing one Ordinary Share
dei Trading Symbol
TradingSymbol
TEVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1120971202
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2249000000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2801000000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
86000000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
91000000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3385000000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3696000000
CY2023Q3 us-gaap Inventory Net
InventoryNet
4051000000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3833000000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1168000000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1162000000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
520000000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
549000000
CY2023Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
51000000
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
10000000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11425000000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12051000000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1748000000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1453000000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
477000000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
441000000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5622000000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5739000000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
419000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5525000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6270000000
CY2023Q3 us-gaap Goodwill
Goodwill
16885000000
CY2022Q4 us-gaap Goodwill
Goodwill
17633000000
CY2023Q3 us-gaap Assets
Assets
42088000000
CY2022Q4 us-gaap Assets
Assets
44006000000
CY2023Q3 us-gaap Debt Current
DebtCurrent
1479000000
CY2022Q4 us-gaap Debt Current
DebtCurrent
2109000000
CY2023Q3 teva Sales Reserves And Allowances
SalesReservesAndAllowances
3351000000
CY2022Q4 teva Sales Reserves And Allowances
SalesReservesAndAllowances
3750000000
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2280000000
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1887000000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
530000000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
566000000
CY2023Q3 teva Accrued Expenses
AccruedExpenses
2741000000
CY2022Q4 teva Accrued Expenses
AccruedExpenses
2151000000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1011000000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1005000000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11394000000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11469000000
CY2023Q3 us-gaap Deferred Tax And Other Liabilities Noncurrent
DeferredTaxAndOtherLiabilitiesNoncurrent
544000000
CY2022Q4 us-gaap Deferred Tax And Other Liabilities Noncurrent
DeferredTaxAndOtherLiabilitiesNoncurrent
548000000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3818000000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3847000000
CY2023Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
18495000000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
19103000000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
324000000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
349000000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
23182000000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
23846000000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Liabilities
Liabilities
34576000000
CY2022Q4 us-gaap Liabilities
Liabilities
35315000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1227000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1217000000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
57000000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
57000000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27780000000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27688000000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13870000000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12882000000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2910000000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2838000000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
106000000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
106000000
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
4128000000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4128000000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6929000000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7897000000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
582000000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
794000000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7512000000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8691000000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42088000000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44006000000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3850000000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3595000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11389000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11041000000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1999000000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1926000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6159000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5839000000
CY2023Q3 us-gaap Gross Profit
GrossProfit
1851000000
CY2022Q3 us-gaap Gross Profit
GrossProfit
1669000000
us-gaap Gross Profit
GrossProfit
5230000000
us-gaap Gross Profit
GrossProfit
5203000000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
253000000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
175000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
726000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
628000000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
576000000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
539000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1726000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1716000000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
268000000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
283000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
870000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
892000000
CY2023Q3 teva Intangible Assets Impairments
IntangibleAssetsImpairments
47000000
CY2022Q3 teva Intangible Assets Impairments
IntangibleAssetsImpairments
24000000
teva Intangible Assets Impairments
IntangibleAssetsImpairments
289000000
teva Intangible Assets Impairments
IntangibleAssetsImpairments
223000000
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
700000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
745000000
CY2023Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
46000000
CY2022Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
36000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
241000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
282000000
CY2023Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
314000000
CY2022Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
195000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
1009000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
2048000000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
9000000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2000000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
43000000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
88000000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
355000000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
419000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-289000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1244000000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280000000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-252000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-808000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-721000000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
75000000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
166000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1097000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1964000000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-12000000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
107000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-48000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-792000000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20000000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88000000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
58000000
us-gaap Profit Loss
ProfitLoss
-1048000000
us-gaap Profit Loss
ProfitLoss
-1152000000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
8000000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-60000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21000000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
80000000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
56000000
us-gaap Net Income Loss
NetIncomeLoss
-988000000
us-gaap Net Income Loss
NetIncomeLoss
-1132000000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1121000000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1111000000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1119000000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1109000000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1135000000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1119000000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1119000000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1109000000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88000000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
58000000
us-gaap Profit Loss
ProfitLoss
-1048000000
us-gaap Profit Loss
ProfitLoss
-1152000000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-255000000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-402000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-173000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-684000000
CY2023Q3 teva Unrealized Gain Loss On Derivative Net Of Tax
UnrealizedGainLossOnDerivativeNetOfTax
7000000
CY2022Q3 teva Unrealized Gain Loss On Derivative Net Of Tax
UnrealizedGainLossOnDerivativeNetOfTax
7000000
teva Unrealized Gain Loss On Derivative Net Of Tax
UnrealizedGainLossOnDerivativeNetOfTax
19000000
teva Unrealized Gain Loss On Derivative Net Of Tax
UnrealizedGainLossOnDerivativeNetOfTax
21000000
CY2023Q3 us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-1000000
CY2022Q3 us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
0
us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-2000000
us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
0
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-249000000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-395000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-156000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-663000000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1002000000
CY2023Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
238000000
CY2022Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-93000000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-161000000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-337000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1204000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1815000000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-8000000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-40000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-144000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-214000000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-153000000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-297000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1060000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1601000000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7708000000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88000000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-249000000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31000000
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
67000000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7512000000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9828000000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
58000000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-395000000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26000000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9519000000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8691000000
us-gaap Profit Loss
ProfitLoss
-1048000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-156000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93000000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
67000000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7512000000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11244000000
us-gaap Profit Loss
ProfitLoss
-1152000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-663000000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
88000000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9519000000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88000000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
58000000
us-gaap Profit Loss
ProfitLoss
-1048000000
us-gaap Profit Loss
ProfitLoss
-1152000000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
283000000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
321000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
887000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1002000000
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
48000000
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
28000000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1010000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
398000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-1007000000
CY2023Q3 teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-199000000
CY2022Q3 teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
44000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-349000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-1214000000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
31000000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
26000000
us-gaap Share Based Compensation
ShareBasedCompensation
93000000
us-gaap Share Based Compensation
ShareBasedCompensation
88000000
CY2023Q3 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-3000000
CY2022Q3 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-40000000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
20000000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-117000000
CY2023Q3 teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
5000000
CY2022Q3 teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
-13000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
31000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
-1000000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5000000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
543000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
184000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
617000000
CY2023Q3 teva Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables
ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
362000000
CY2022Q3 teva Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables
ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
262000000
teva Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables
ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
1056000000
teva Proceeds From Beneficial Interest In Exchange For Securitized Trade Receivables
ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
854000000
CY2023Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
149000000
CY2022Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
122000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
407000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
406000000
CY2023Q3 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
10000000
CY2022Q3 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
2000000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
68000000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
45000000
CY2023Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2022Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
7000000
CY2023Q3 teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
38000000
CY2022Q3 teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
-2000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
44000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
2000000
CY2023Q3 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1000000
CY2022Q3 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
6000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-4000000
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
184000000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
147000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
667000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
488000000
CY2023Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000000
CY2022Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
365000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4152000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
661000000
CY2023Q3 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2022Q3 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
2451000000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2023Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
700000000
CY2022Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
700000000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2023Q3 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
200000000
CY2022Q3 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
200000000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
CY2023Q3 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-76000000
CY2022Q3 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-75000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-136000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-115000000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-576000000
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-439000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1337000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-776000000
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000000
CY2022Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-84000000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-98000000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-269000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-420000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
167000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-584000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60000000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2670000000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2091000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2834000000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2198000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2250000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2258000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2250000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2258000000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2249000000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2225000000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2249000000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2225000000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000
CY2023Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
51000000
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
10000000
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
11000000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
33000000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
33000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2250000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2258000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2250000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2258000000
CY2023Q3 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
376000000
CY2022Q3 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
293000000
teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
1090000000
teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
883000000
CY2023Q3 teva Dividend Declared To Noncontrolling Interests
DividendDeclaredToNoncontrollingInterests
67000000
CY2022Q3 teva Dividend Declared To Noncontrolling Interests
DividendDeclaredToNoncontrollingInterests
0
teva Dividend Declared To Noncontrolling Interests
DividendDeclaredToNoncontrollingInterests
67000000
teva Dividend Declared To Noncontrolling Interests
DividendDeclaredToNoncontrollingInterests
0
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
7000000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
2000000
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
25000000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
18000000
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Goodwill Current
DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
19000000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Goodwill Current
DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
0
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-10000000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3850000000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3595000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11389000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11041000000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3817000000
teva Valuation Allowances And Reserves Related To Current Period Sales
ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
9612000000
teva Valuation Allowances And Reserves Related To Prior Period Sales
ValuationAllowancesAndReservesRelatedToPriorPeriodSales
-52000000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
9946000000
teva Valuation Allowances And Reserves Foreign Currency Translation
ValuationAllowancesAndReservesForeignCurrencyTranslation
-19000000
CY2023Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3412000000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
4309000000
teva Valuation Allowances And Reserves Related To Current Period Sales
ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
9886000000
teva Valuation Allowances And Reserves Related To Prior Period Sales
ValuationAllowancesAndReservesRelatedToPriorPeriodSales
-158000000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
10231000000
teva Valuation Allowances And Reserves Foreign Currency Translation
ValuationAllowancesAndReservesForeignCurrencyTranslation
-106000000
CY2022Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3700000000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2171000000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1987000000
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1106000000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1059000000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
590000000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
555000000
CY2023Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
184000000
CY2022Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
232000000
CY2023Q3 us-gaap Inventory Net
InventoryNet
4051000000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3833000000
CY2023Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
83000000
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
78000000
CY2023Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
18495000000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
19103000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18714000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19131000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13189000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12861000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5525000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6270000000
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145000000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
165000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
471000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
576000000
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
47000000
CY2022Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
24000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
289000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
223000000
CY2022Q4 us-gaap Goodwill
Goodwill
17633000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
700000000
teva Goodwill Reclassification
GoodwillReclassification
-19000000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
29000000
CY2023Q3 us-gaap Goodwill
Goodwill
16885000000
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
28300000000
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
27600000000
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
700000000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
956000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2086000000
CY2023Q3 us-gaap Debt Current
DebtCurrent
1479000000
CY2022Q4 us-gaap Debt Current
DebtCurrent
2109000000
CY2023Q3 us-gaap Senior Notes
SeniorNotes
19533000000
CY2022Q4 us-gaap Senior Notes
SeniorNotes
21266000000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
956000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2086000000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1009000000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2048000000
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
4905000000
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
4186000000
CY2023Q3 teva Damages Assessment
DamagesAssessment
235500000
CY2023Q3 teva Long Term Debt Currency Portion Usd
LongTermDebtCurrencyPortionUSD
0.62
CY2023Q3 teva Long Term Debt Currency Portion Eur
LongTermDebtCurrencyPortionEUR
0.36
CY2023Q3 teva Long Term Debt Currency Portion Chf
LongTermDebtCurrencyPortionCHF
0.02
CY2023Q3 teva Revenues Other Than Usd
RevenuesOtherThanUsd
0.47
CY2023Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
22000000
CY2022Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
34000000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
20000000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
69000000
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
493000000
CY2023Q3 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
7000000
CY2022Q3 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
8000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
25000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
22000000
CY2023Q4 teva Derivative Notional Amount Decrease
DerivativeNotionalAmountDecrease
125000000
CY2023Q3 us-gaap Supplier Finance Program Obligation
SupplierFinanceProgramObligation
85000000
CY2022Q4 us-gaap Supplier Finance Program Obligation
SupplierFinanceProgramObligation
34000000
CY2023Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
314000000
CY2022Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
195000000
CY2021Q3 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
235500000
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
60500000
CY2018Q3 teva Annual Sales Of Effexor
AnnualSalesOfEffexor
2600000000
CY2005Q1 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
950000000
CY2008Q3 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
2300000000
CY2013Q2 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
416000000
CY2013Q3 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
1100000000
CY2010Q4 teva Annual Sales Of Actos
AnnualSalesOfActos
3700000000
CY2010Q4 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
500000000
CY2012Q3 teva Annual Sales Of Actos
AnnualSalesOfActos
2800000000
CY2012Q3 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
430000000
CY2019 teva Annual Sales Of Sensipar
AnnualSalesOfSensipar
1400000000
CY2019Q3 teva Annual Sales At Time Of Settlement
AnnualSalesAtTimeOfSettlement
350000000
CY2023Q3 teva Annual Sales At Time Of Settlement
AnnualSalesAtTimeOfSettlement
700000000
teva Annual Sales Of The Time Of Settlement Of Viread
AnnualSalesOfTheTimeOfSettlementOfViread
582000000
teva Annual Sales Of The Time Of Settlement Of Truvada
AnnualSalesOfTheTimeOfSettlementOfTruvada
2400000000
teva Annual Sales Of The Time Of Settlement Of Atripla
AnnualSalesOfTheTimeOfSettlementOfAtripla
2900000000
CY2017 teva Annual Sales Of The Time Of New Launch Of Viread
AnnualSalesOfTheTimeOfNewLaunchOfViread
728000000
CY2020 teva Annual Sales Of The Time Of New Launch Of Truvada
AnnualSalesOfTheTimeOfNewLaunchOfTruvada
2100000000
CY2020 teva Annual Sales Of The Time Of New Launch Of Atripla
AnnualSalesOfTheTimeOfNewLaunchOfAtripla
444000000
CY2021 teva Annual Sales Of Copaxone
AnnualSalesOfCopaxone
373000000
CY2022 teva Annual Sales Of Colcrys
AnnualSalesOfColcrys
187000000
teva Annual Sales Of Revlimid
AnnualSalesOfRevlimid
3500000000
CY2022Q4 teva Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With An Anda Filer
AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler
300000000
CY2022Q4 teva Annual Sales Of Epipen
AnnualSalesOfEpipen
600000000
CY2022Q4 teva Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population
LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation
1000000000000
CY2022Q4 teva Percentage Of Share Of The National Population
PercentageOfShareOfTheNationalPopulation
0.01
teva Percentage Of The Litigating Subdivisions Have Chosen To Participate In Tevas Nationwide Settlement
PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement
0.99
CY2023Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
4250000000
CY2023Q2 teva Litigation Settlement Amount Awarded Distribution Period
LitigationSettlementAmountAwardedDistributionPeriod
P13Y
CY2023Q3 teva Litigation Settlement Amount Distributablein Kind
LitigationSettlementAmountDistributableinKind
1200000000
CY2023Q3 teva Litigation Settlement Amount Payable In Cash Percentage
LitigationSettlementAmountPayableInCashPercentage
0.20
CY2023Q3 teva Litigation Settlement Amount Distributable In Cash
LitigationSettlementAmountDistributableInCash
240000000
CY2023Q3 us-gaap Accrual For Environmental Loss Contingencies
AccrualForEnvironmentalLossContingencies
300000
CY2021Q3 teva Loss Contingencies On Environmental Laws Penalty
LossContingenciesOnEnvironmentalLawsPenalty
1400000
CY2022Q4 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
176500000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-12000000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
75000000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
107000000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
166000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-48000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1097000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-792000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1964000000
teva Expected Impairment Of Income Tax Benefit
ExpectedImpairmentOfIncomeTaxBenefit
126000000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1000000
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
4000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
21000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
34000000
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
16000000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
6000000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
106000000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
27000000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
25000000
us-gaap Restructuring Charges
RestructuringCharges
93000000
us-gaap Restructuring Charges
RestructuringCharges
117000000
CY2023Q3 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
2000000
CY2022Q3 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
1000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
21000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
31000000
CY2023Q3 teva Impairment And Restructuring
ImpairmentAndRestructuring
46000000
CY2022Q3 teva Impairment And Restructuring
ImpairmentAndRestructuring
36000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
241000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
282000000
CY2023Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1000000
CY2022Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
4000000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
21000000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
34000000
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
16000000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
6000000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
106000000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
27000000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
25000000
us-gaap Restructuring Charges
RestructuringCharges
93000000
us-gaap Restructuring Charges
RestructuringCharges
117000000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
27000000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
25000000
us-gaap Restructuring Charges
RestructuringCharges
93000000
us-gaap Restructuring Charges
RestructuringCharges
117000000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
119000000
teva Restructuring Accrual Provision
RestructuringAccrualProvision
93000000
teva Utilization And Other
UtilizationAndOther
130000000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
82000000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
138000000
teva Restructuring Accrual Provision
RestructuringAccrualProvision
117000000
teva Utilization And Other
UtilizationAndOther
136000000
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
119000000
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1135000000
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1119000000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1119000000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1109000000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
84000000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
193000000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
145000000
CY2022Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
165000000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
471000000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
576000000
CY2023Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
46000000
CY2022Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
36000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
241000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
282000000
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
700000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
745000000
CY2023Q3 teva Intangible Assets Impairments
IntangibleAssetsImpairments
47000000
CY2022Q3 teva Intangible Assets Impairments
IntangibleAssetsImpairments
24000000
teva Intangible Assets Impairments
IntangibleAssetsImpairments
289000000
teva Intangible Assets Impairments
IntangibleAssetsImpairments
223000000
CY2023Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
314000000
CY2022Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
195000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
1009000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
2048000000
CY2023Q3 teva Other Unallocated Amounts
OtherUnallocatedAmounts
112000000
CY2022Q3 teva Other Unallocated Amounts
OtherUnallocatedAmounts
139000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
394000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
379000000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
355000000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
419000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-289000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1244000000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280000000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-252000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-808000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-721000000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
75000000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
166000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1097000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1964000000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1000000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
68000000
CY2023Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
2252000000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
33000000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
153000000
CY2022Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
2624000000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
152000000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
175000000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
28000000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
112000000
CY2023Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
17604000000
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
18769000000

Files In Submission

Name View Source Status
teva-20230930_cal.xml Edgar Link unprocessable
0001193125-23-274495-index-headers.html Edgar Link pending
0001193125-23-274495-index.html Edgar Link pending
0001193125-23-274495.txt Edgar Link pending
0001193125-23-274495-xbrl.zip Edgar Link pending
d538891d10q.htm Edgar Link pending
d538891dex311.htm Edgar Link pending
d538891dex312.htm Edgar Link pending
d538891dex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d538891d10q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
teva-20230930.xsd Edgar Link pending
teva-20230930_def.xml Edgar Link unprocessable
teva-20230930_lab.xml Edgar Link unprocessable
teva-20230930_pre.xml Edgar Link unprocessable